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Objective: To examine the acceptability and feasibility of mobile health (mHealth)/short 
message service (SMS) and community-based directly observed antiretroviral therapy (cDOT) 
as interventions to improve antiretroviral therapy (ART) adherence for preventing mother- 
to-child human immunodeficiency virus (HIV) transmission (PMTCT).
Design and methods: A mixed-method approach was used. Two qualitative focus group 
discussions with HIV-infected pregnant women (n=20) examined the acceptability and feasi-
bility of two ART adherence interventions for PMTCT: 1) SMS text messaging and 2) patient-
nominated cDOT supporters. Additionally, 109 HIV-infected, pregnant South African women 
(18–30 years old) receiving PMTCT services under single-tablet antiretroviral therapy regimen 
during pregnancy and breastfeeding and continuing for life (“Option B+”) were interviewed 
about mobile phone access, SMS use, and potential treatment supporters.
Setting: A community primary care clinic in Cape Town, South Africa.
Participants: HIV-infected pregnant women.
Main outcomes: Acceptability and feasibility of mHealth and cDOT interventions.
Results: Among the 109 women interviewed, individual mobile phone access and SMS use 
were high (.90%), and 88.1% of women were interested in receiving SMS ART adherence 
support messages such as reminders, motivation, and medication updates. Nearly all women 
(95%) identified at least one person close to them to whom they had disclosed their HIV status 
and would nominate as a cDOT supporter. Focus group discussions revealed that cDOT sup-
porters and adherence text messages were valued, but some concerns regarding supporter time 
availability and risk of unintended HIV status disclosure were expressed.
Conclusion: mHealth and/or cDOT supporter as interventions to improve ART adherence 
are feasible in this setting. However, safe HIV status disclosure to treatment supporters and 
confidentiality of text messaging content about HIV and ART were deemed crucial.
Keywords: HIV, AIDS, pregnancy, short messaging system, social support
Introduction
Annually, nearly 1.4 million human immunodeficiency virus (HIV)-infected women 
give birth worldwide, and nearly all (.90%) reside in low- or middle-income coun-
tries where breastfeeding is common and access to prevention of mother-to-child HIV 
transmission (PMTCT) services may be limited.1 Indeed, in some sub-Saharan settings, 
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due to lack of or late access to or suboptimal antiretroviral 
therapy (ART), HIV mother-to-child HIV transmission 
(MTCT) rates range from 25% to 48%.1,2 In contrast, in 
high-income countries, MTCT rates as low as 1%–2% or less 
have been achieved through effective combination of ART 
and breastfeeding avoidance.3 The success of this approach, 
coupled with a once-daily single-pill combination regimen, 
the increasing acknowledgment of the benefits of early treat-
ment and the role of ART in preventing sexual transmission, 
evidence of protection against MTCT during breastfeeding, 
and simplification of program implementation have led the 
World Health Organization to recommend a single once-daily 
regimen during pregnancy and breastfeeding and continuing 
for life (Option B+), especially in generalized epidemics, 
regardless of CD4+ T-cell count.4 But concerns have been 
raised regarding the risk of ART adherence fatigue, with 
resulting virological failure and drug resistance among 
women enrolled in Option B+ regimens, as well as questions 
regarding the need to continue ART in the postpartum period 
among women in relatively good health.5
Low ART adherence among pregnant and recently 
delivered women impairs the effectiveness of PMTCT 
programs and may compromise long-term maternal health. 
A meta-analysis of ART adherence studies conducted 
among pregnant women in low-, middle- and high-income 
settings (51 studies, N=20,153) in the pre-Option B+ era 
revealed that only 75.7% had optimal ($80%) antepartum 
adherence, declining to 50.3% during the postpartum period.5 
Furthermore, women progressing through the postpartum 
period become more susceptible to “falling off the cliff” 
of the PMTCT treatment cascade.6 Evidence suggests that 
barriers to ART adherence among pregnant and recently 
delivered women include physical and depressive symp-
toms, forgetfulness, substance abuse, fear of HIV status 
disclosure, regimen fatigue, competing priorities, and lack 
of social support.7 Other recently identified barriers include 
concerns of gender inequity in treatment, food insecurity, 
and HIV disclosure.8,9 Despite the critical need for PMTCT 
during pregnancy and the postpartum period, evidence-based 
interventions to promote ART adherence during this period, 
particularly in the context of Option B+, are lacking.10
Mobile health (mHealth) and directly observed therapy 
(DOT) improve ART adherence in HIV-infected adults, in 
general.11–16 For example, weekly two-way interactive short 
message service (SMS) text messages significantly improved 
ART adherence and virological suppression in Kenyan 
HIV-infected adults.17 In South Africa, community-based 
directly observed antiretroviral therapy (cDOT) provided 
by patient-nominated community supporters such as friends 
and family, was associated with improved CD4+ T-cell count 
at 6 months follow-up and reduced AIDS-related mortality 
at 24 months follow-up.13 Coupling real-time mobile SMS 
with patient-nominated cDOT supporters may provide two 
powerful interventions to improve ART outcomes among 
women enrolled in PMTCT services.17 Little is known, how-
ever, regarding the acceptability of mobile SMS and cDOT, 
individually or in combination, among pregnant and recently 
delivered women.18 Attention to adherence support may be 
of particular importance in these women, who may have first 
learned of their HIV infection in pregnancy and have not been 
afforded the time for acceptance and treatment readiness.
This study used a mixed-methods approach to examine 
the acceptability and feasibility of mHealth and cDOT 
as possible interventions to improve ART adherence for 
PMTCT outcomes in HIV-infected South African pregnant 
women. We explored access to mobile phones, preferences 
for patient-nominated cDOT supporters, and use of mHealth 
in this population, with the ultimate aim to improve their ART 
adherence, virological, and immunological outcomes, and to 
decrease the risks of HIV transmission to their infants.
Design and methods
study population
The study population was recruited from the Michael 
Mapongwana Community HIV primary care clinic in 
Khayelitsha, a township outside the city of Cape Town, 
South Africa, from December 2014 to January 2015. PMTCT 
services, including ART initiation and adherence support, 
are provided each month at the clinic to ~1,000 HIV-infected 
pregnant and postpartum women. Of note, Western Cape is 
the only province in South Africa where Option B+ (once-
daily single tablet antiretroviral regimen during pregnancy 
and breastfeeding and continuing for life) is currently being 
implemented, pending countrywide expansion.
Procedures
A mixed-methods approach was used, including 1) two 
focus group discussions (FGDs) with 20 HIV-positive 
clinic-attending pregnant women on the acceptability and 
feasibility of a proposed SMS/cDOT adherence intervention 
(qualitative) and 2) individual structured interviews with 
HIV-positive pregnant women (n=109) to assess mobile phone 
access, SMS literacy, HIV disclosure, and interest in and avail-
ability of patient-nominated cDOT supporters (quantitative).
Qualitative phase
Pregnant women were recruited purposively by a clinic-based 
study nurse, based on the following characteristics: $18 years 
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old, documented HIV seropositive, on ART or about to initiate 
ART, and able to give consent. The study nurse explained the 
study to potential participants and referred interested women 
to a study coordinator who obtained full informed consent 
and recruited them into one of the two focus groups. Both 
FGDs were led by a trained social scientist with qualitative 
research experience, using an open-ended interview guide 
to explore the following domains: 1) potential benefits and 
barriers of using an mHealth and patient-nominated cDOT 
supporter intervention to improve ART adherence and 2) how 
the context of pregnancy and the post-childbirth period may 
affect the use of mobile or cDOT supporter components of 
the proposed intervention. Each session, ~45 minutes in 
duration, was conducted in the local language (Xhosa), audio 
recorded, and transcribed for analysis.
The interview guide was based upon a proposed conceptual 
framework, focusing on social support, reciprocity, and social 
network and role theories to elucidate the social dynamics of 
introducing and reinforcing norms of ART adherence and 
assistance in existing salient roles (support network members 
and medical providers). By bolstering the adherence support 
functioning of existing support networks and clinic providers, 
the study addresses key influences on ART adherence. In addi-
tion, the conceptual model includes text messages as a form 
of social support as well as information (Figure 1).
Quantitative phase
HIV-positive pregnant women aged 18 years or older, on 
ART or about to start ART and able to give consent, were 
recruited sequentially from the Michael Mapongwana HIV 
care clinic to complete an individual structured interview 
assessing 1) the use of cell phones; 2) acceptance of the 
use of text messaging for health messages intervention 
purposes; and 3) availability of support person(s) as a 
possible intervention for ART adherence. The survey 
took ~15 minutes to complete and was administered in the 
local language (Xhosa) by a skilled female field worker 
with previous clinical and survey research experience. 
The target sample size was derived to achieve precision 
of ±5% around proportions with 80% power and a type 1 
error of 5%.
statistical analysis
All qualitative data were transcribed, translated to English, 
and coded in Atlas-Ti Version 7.0 software (ATLAS.ti Scien-
tific Software Development GmbH, Berlin, Germany; http://
atlasti.com/). The FGD transcripts were iteratively reviewed 
and a codebook was developed based on the study’s objec-
tive and emerging themes in the data. A content thematic 
analysis approach was then used to identify the common 
preferences and concerns among women regarding the 
proposed intervention.19 Descriptive statistics (eg, mean, 
frequency, proportions) were used to summarize data from 
the structured survey using STATA, Version 11 (StataCorp 
LP, College Station, TX, USA).
ethical approvals
Ethical approval was provided by the Stellenbosch University 
Research Ethics Committee and the Western Cape Province 
Government, Department of Health/Ministry of Health. 
Written informed consent was obtained from all study 
participants prior to enrollment.
Figure 1 Conceptual framework: social environmental influences on medical adherence among HIV-positive pregnant and postnatal women.
Abbreviations: ART, antiretroviral therapy; dx, diagnosed; HIV, human immunodeficiency virus; mHealth, mobile health; PCR, polymerase chain reaction; SMS, short 
message service.
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Results
Qualitative phase
In FGDs, topics addressed included 1) acceptability and 
preferred content of SMS messaging; 2) concerns related to 
confidentiality of messaging; and 3) acceptability of patient-
nominated cDOT supporters.
The most commonly preferred adherence-related mes-
sages were reminders to take ART medication and attend 
clinic appointments, credible information on ART drug 
regimens for HIV-infected pregnant women, and motivational 
messages to let them know they were not alone. As three 
women described:
If they [SMS messages] can remind us about the times of 
taking the pills or the dates of coming to the clinic. The 
SMS’s must also be educational about taking your pills 
and if you don’t take them, this and this will happen to 
you. [FGD woman]
Things like [information on] support groups like this one 
also helping because it’s where you see that you are not 
alone. There are people that are going through the same 
problem as you. [FGD woman]
I think it [SMS] will help a lot because sometimes after 
finding out about your status you still feel lost and don’t 
have any information about HIV. The only thing you know 
is the stuff you hear from other people so if you get SMS’s 
that support you it will help you. [FGD woman]
Women in FGDs revealed concerns that other people 
would see the ART adherence text messages and find out 
about their HIV status. For some women, their diagnosis of 
HIV was relatively new, and they had not yet fully absorbed 
what their diagnosis meant for them and their families. The 
move to a new community, as some women reported, con-
stituted a “protection” and an impetus for the move was that 
no one would know their HIV status. These women felt they 
could restart their social lives and keep their status hidden. 
As one woman described:
It’s when you didn’t disclose your status and then someone 
get hold of your phone. I used to stay in the Eastern Cape 
but then I moved to Cape Town. It was easier [to take ART] 
because they don’t know me here. But if people don’t know 
about your status, it’s hard because you’re scared that people 
are going to see you take them. [FGD woman]
Several findings also emerged regarding the acceptability of 
patient-nominated cDOT supporters during the study’s FGDs. 
Women liked the idea of being supported by patient-nominated 
relatives or friends. When asked about the potential advantages/
benefits of using a patient-nominated treatment supporter to 
provide daily cDOT, two women commented:
I think that person will be good for supporting you; like 
she said some people get dizzy after taking ART so if you 
faint and the person who knows about you taking ART will 
make things easier. [FGD woman]
The person will also make sure that you go to the clinic and 
you take your ART on time. [FGD woman]
Some women were uncertain whether all cDOT sup-
porters could be relied upon to be consistently available and 
actively engaged. As one woman described:
I think that SMS system will help more than the patient-
nominated supporter; people have their own problems. What 
if they have a problem and they can’t make it to me? But 
both are good in their own different ways. And you can’t 
really trust people because that person can talk about you 
to other people. [FGD woman]
Finally, the discussions revealed some confusion about 
participants’ knowledge about HIV and the role of ART, 
including why adherence is important. They recognized the 
role of ART in protecting HIV-exposed babies but were often 
unclear of the impact of ART on HIV-infected pregnant and 
recently delivered women, including concerns regarding 
drug-related side effects and confusion about the effects 
of ART on tuberculosis and other sexually transmitted 
infections. For example, one woman explained:
I think as a person who is HIV positive there are many 
things that you can catch, so if you take your ART you can 
protect the baby. And at the same time, you keep the virus 
under control so that it cannot spread more. You can also 
get STIs [sexually transmitted infections] so you must take 
ART to protect your child. [FGD woman]
I haven’t experienced anything, like I heard people say if 
you take ARVs you will get side effects but I never expe-
rienced that. [FGD woman]
Some people say it’s because of the side effects; because 
some vomit, others get a rash or nauseous. And not getting 
enough counselling and education or explanation about the 
ARVs. [FGD woman]
Quantitative phase
Participants (n=109) in the quantitative phase ranged from 
18 to 30 years of age. Nearly all (99.1%) owned a mobile 
 
Pa
tie
nt
 P
re
fe
re
nc
e 
an
d 
Ad
he
re
nc
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
6.
23
2.
12
5.
10
8 
on
 1
3-
Se
p-
20
17
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Patient Preference and Adherence 2016:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
687
mhealth and social support for PMTcT
phone, and nearly all (88.1%) women were interested in 
receiving SMS adherence support messages for reminders, 
motivation, and drug updates. SMS literacy was high with 
107 (98.2%) women regularly using SMS text messages to 
communicate with family (83.5%), male partners (53.2%), and 
friends (41.3%). No participants reported using SMS regu-
larly to correspond with community health workers. Only 20 
(18.3%) women reported having received health educational 
text messages. All women reported having at least one person 
in their network to whom they felt comfortable disclosing 
their HIV status and discussing ART adherence. One hundred 
and six (97.5%) were prepared to share the name and contact 
details of a potential nominated cDOT supporter for the pro-
posed intervention. Additional interview results, including 
those related to preferences for SMS messages and individuals 
with whom they would feel comfortable discussing HIV and 
adherence-related issues, are reported in Table 1.
Discussion
This study provides preliminary data on acceptability and 
feasibility of an mHealth and/or cDOT treatment supporter 
intervention for women receiving PMTCT in South Africa. 
Important findings from this mixed-methods study showed 
that individual mobile phone access and cell phone literacy 
were high (.90%) and that nearly all (88.1%) women were 
interested in receiving SMS adherence support messages 
as reminders, motivation, and drug updates. The high 
penetration of mobile phone technology in HIV-infected 
pregnant women and its acceptability suggest its utility to 
improve PMTCT outcomes. Nevertheless, only a small 
minority (,20%) had already used mobile phone com-
munications for their health management, suggesting an 
opportunity for a structured mHealth intervention. In addi-
tion, qualitative findings provided important insights into 
how message reminders must be tailored to avoid disclosing 
someone’s HIV status to others. In several other studies on 
HIV-infected persons, text-based messaging has been sup-
ported as a platform for providing prompt and confidential 
behavioral change and motivational support messages, but 
this has not been evaluated in HIV-infected pregnant and 
breastfeeding women as an additional intervention for 
PMTCT.20–23
Certain mHealth interventions using SMS are effective 
in promoting adherence to ART medications.24–26 Tailored 
message content and timing appear to have a critical role in 
the impact of SMS interventions.26 Current evidence suggests 
superiority of two-way text messaging interventions over a 
one-way (more passive) mode of providing ART medica-
tion reminders.27,28 Our study shows that tailored messages 
also appear promising for PMTCT, although most existing 
research has yet to demonstrate the effectiveness of one-way 
messages.26 Pop-Eleches et al14 tested both daily and weekly 
messages and found that weekly messages improved ART 
adherence, whereas daily messages did not. WelTel Kenya 
participants reported that their weekly two-way messages 
made them feel “like someone cares”.11
An important issue revealed by the study participants was 
the risk of unintended disclosure of HIV status when using 
mHealth to promote ART adherence. This can be under-
stood in the context of variable HIV disclosure rates among 
pregnant and postpartum women in sub-Saharan Africa; a 
recent systematic review found that although across 47 stud-
ies, 67% of HIV-infected pregnant and postpartum women in 
sub-Saharan Africa had disclosed their HIV status to another 
person, these rates varied widely (ie, from 5% to 97%).29 
Therefore, in order to promote acceptability, text messages 
should use neutral language (not specifically mention 
ART/HIV), as well as use euphemistic terms for ART, other 
medications, and types of clinic visits. This is a primary 
reason why nonmedical language such as “Mambo?”/“Are 
Table 1 results of quantitative phase (structured interviews; n=109)
Topics N %
Mobile cell use
Ownership of cell phones 108 99.1
Use sMs messaging 107 98.2
Who participants SMS message with
Family 92 83.5
Partner 58 53.2
Friends 45 41.3
community volunteers 0 0
health workers 1 0.9
Attitudes to mHealth
has received health messages on phone? 20 18.3
Willing to use cell phone in trial? 96 88.1
Preferences regarding frequency of SMS  
messages for an intervention
Daily 22 20.2
Weekly 50 45.9
Monthly 25 22.9
Other 12 11.0
Others with whom participants talk to  
about HIV status
Family 56 51.4
Partner 32 29.4
Friends 16 14.7
community volunteers 2 2.8
health care workers 43 39.4
Only to health staff 28 25.7
Treatment supporters
share name of potential supporter 106 97.2
Abbreviations: HIV, human immunodeficiency virus; mHealth, mobile health; SMS, 
short message service.
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You OK” was/is used in the WelTel Kenya trial by Lester 
et al.12 Participants were/are instructed to indicate within 
48 hours of receiving the message either that they are doing 
well (eg, “OK”) or that they have a problem (eg, “Prob-
lem”). If a problem is reported, the participant will receive a 
follow-up support/ART adherence counseling call from the 
study team. With this approach, no accidental disclosures 
have been reported with over 3,000 participants thus far.12 
Also, our data are in agreement with Jennings et al18 in Kenya 
who found that although PMTCT adherence text messages 
would need to protect against unintended HIV disclosure, 
women were eager to receive real-time support messages 
for adherence and motivation.
Unintended disclosure was also a concern in a recently 
published qualitative study aiming to develop text message 
content in Kenya for an mHealth study to improve postpartum 
retention in PMTCT and early infant HIV diagnosis. This 
study also suggested that the SMS messages incorporate 
motivational messages to engage women in care, particu-
larly by focusing on the child’s health needs (eg, child’s 
clinic-based immunizations).30 Also, the implementation of 
mHealth in western Kenya has proven feasible and effective 
in tracking and improving the treatment-seeking behavior of 
pregnant women, during pregnancy, until 18 months follow-
ing delivery, and could therefore effectively complement the 
ongoing PMTCT efforts to reach the goal of virtual elimina-
tion in sub-Saharan Africa.31
Regarding patient-nominated cDOT supporters, the 
qualitative data illustrate the important role of social sup-
port to meet maternal health and HIV-related needs. Social 
support typically includes emotional support (ie, providing 
love, empathy), instrumental or “tangible” support, infor-
mational support (ie, problem solving and guidance), and/
or social companionship, which can provide a feeling of 
connection, belonging, and/or affirmation.32,33 Our qualita-
tive data point specifically to the need for instrumental and 
emotional support during pregnancy, which is reflected in 
our conceptual model (Figure 1). This finding is in line with 
prior qualitative research pointing to the role of social sup-
port in understanding successful adherence in sub-Saharan 
Africa, referring to how individuals can overcome obstacles 
to adherence in a large part due to resources made avail-
able by treatment supporters, family, friends, and health 
care providers; further, this support is reciprocal, such that 
adherence follows to fulfill a perceived responsibility to 
one’s supporters.34
These findings are consistent with other studies examin-
ing the acceptability of cDOT interventions in the general 
HIV population in which a family member such as a mother, 
sibling, or friend (irrespective of HIV status) was a more 
commonly preferred ART treatment supporter, compared 
to sexual partners, who were least mentioned as a preferred 
supporter.35 Only in long-term, stable relationships, with HIV 
status mutually disclosed, were sexual partners reported as 
important sources of social support and potentially effec-
tive candidates for community-based ART DOT.35 This 
evidence suggests that effective cDOT interventions among 
pregnant and postpartum women should be family based, 
rather than couples based, in order to improve maternal 
and newborn ART outcomes. Our study provides important 
clinical implications to guide the design and evaluation of 
future and novel HIV treatment adherence interventions in 
pregnant and postpartum women. mHealth and/or cDOT 
supporter interventions for PMTCT should address issues 
related to safe disclosure of HIV status to treatment supporter. 
Maintenance of confidentiality in SMS messages intended to 
educate patients about HIV and ART will promote accept-
ability and feasibility of this intervention. There is a critical 
need to evaluate the effectiveness and cost-effectiveness 
of these interventions singularly or in combination (eg, by 
factorial design to allow precise determination of component 
intervention and interaction effects) through well-controlled 
randomized trials in this underresearched HIV-infected preg-
nant and postpartum women.36
Pregnancy and the immediate postpartum period (eg, 
breastfeeding) is a key opportunity for using community- or 
home (family)-based DOT-ART by providing targeted social 
support needed to address specific individual, structural, 
and social barriers to ART adherence experienced by this 
vulnerable population. In a mathematical simulation model, 
McCabe et al37 found that DOT was associated with a relative 
risk of HIV transmission of 0.39 compared to conventional 
ART, highly cost-effective in the cohort as a whole (cost–
utility ratio $14,233 per QALY), and cost-saving in women 
whose plasma HIV-1 RNA on self-administered ART would 
have exceeded 1,000 copies/mL. The results were stable in 
wide-ranging sensitivity analyses, with DOT being cost-
saving or highly cost-effective in almost all cases.37
This study is limited due to its cross-sectional nature. This 
does not allow us to determine how relationships and feelings 
about the proposed interventions may change over time or 
how acceptability and feasibility may change after birth since 
all women were still pregnant. Also, our study draws upon 
a small number of focus groups for which we used conve-
nience sampling. Therefore, some preferences among women 
for PMTCT-related text messaging and cDOT supporter 
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mhealth and social support for PMTcT
interventions may not have been captured. To mitigate this 
potential limitation, we invited enrolled women to share as 
many of their opinions as possible, enabling the study to report 
on a range of important considerations for effective mHealth 
and cDOT components for PMTCT. In addition, the study 
did neither assess women’s perceptions of training needs for 
effective cDOT supporters nor explore the preferred methods 
of using SMS for PMTCT. The study’s findings are also rep-
resentative of HIV-positive women who are currently seeking 
treatment and engaged in PMTCT care, therefore providing 
more positive responses than from noncare-seeking pregnant 
and postpartum women. Nevertheless, findings from this study 
include timely and valuable acceptability and feasibility data 
to support developing and designing these two novel low-cost 
ART adherence interventions. The implementation of these 
two interventions, either alone or in combination, may provide 
important support for this vulnerable population. These home- 
and community-based interventions shift point of care and 
tasks from health clinics and health care providers to friends 
and/or family members in communities, and therefore, are 
likely to be easily scalable and cost-effective.
Conclusion
Our findings indicate that mHealth and patient-nominated 
treatment supporters are acceptable and potentially promis-
ing interventions to support adherence to PMTCT. However, 
issues related to confidential SMS messaging require atten-
tion to avoid unintended disclosure. These include orientat-
ing family-based adherence supporters on issues of privacy, 
correct ART use, and timely engagement. Future research 
may also examine how best to link SMS adherence mes-
saging among pregnant and postpartum women with cDOT 
supporter communication to interventions targeting other 
structural and psychosocial barriers (ie, depression, substance 
abuse) in support of lifelong ART adherence.
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